Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | F9 | P00740 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27320738 | 0.81 | KDM1A (0.48) | ABCG2CDC7EGFRTP53F9 | |
| SCHEMBL28618764 | 0.78 | ABCG2 (0.54) | ABCG2CDC7EGFRTP53SLC2A1 | |
| SCHEMBL31235691 | 0.78 | ABCG2 (0.54) | ABCG2CDC7EGFRTP53SLC2A1 | |
| SCHEMBL374148 | 0.77 | EGFR (0.71) | TNNI3KEGFRMEN1NPC1RAB9A | |
| SCHEMBL18398024 | 0.77 | CYP1A2 (0.64) | MEN1KMT2A | |
| SCHEMBL12262248 | 0.76 | EGFR (0.52) | TNNI3KABCG2EGFRMEN1NPC1 | |
| SCHEMBL582624 | 0.76 | EPHB4 (0.58) | ABCG2CDC7EGFRSLC2A1NPC1 | |
| SCHEMBL361389 | 0.75 | MAPT (0.53) | ABCG2CDC7SLC2A1MEN1NPC1 | |
| SCHEMBL953597 | 0.75 | ALDH1A1 (0.56) | ABCG2CDC7EGFRSLC2A1MEN1 | |
| SCHEMBL374904 | 0.75 | TNNI3K (0.57) | TNNI3KEGFRMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| CN-103121973-A | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG | 2013-05-29 | — | — | CN | disclosed |
| CN-103121972-A | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG | 2013-05-29 | — | — | CN | disclosed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2409969-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | TNNI3K 149/4885ABCG2 1829/4885CDC7 451/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | TNNI3K 149/4885ABCG2 1829/4885CDC7 451/4885 |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | TNNI3K 149/4885ABCG2 1829/4885CDC7 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.